Skip to content
GILEADGILEADGILEAD701701701

Drawing based on the label description. No photo yet.

“Tablet: 200 mg of emtricitabine and 300 mg of tenofovir DF (equivalent to 245 mg of tenofovir disoproxil): blue, capsule shaped, film coated, debossed with "GILEAD" on one side and with "701" on the other side”

GILEAD 701 pill

Pill with imprint GILEAD 701 is blue, capsule, 19 mm and has been identified as Truvada 200 mg / 300 mg. It is used for HIV and hepatitis B. It is supplied by Redpharm Drug, Inc.

Truvada 200 mg / 300 mg

Imprint
GILEAD 701
Strength
Emtricitabine 200 mg / Tenofovir Disoproxil Fumarate 300 mg
Used for
HIV and hepatitis B
Color
Blue
Shape
Capsule / oblong
Size
19 mm
Score
No score line
Form
Tablet, film coated
Manufacturer
Redpharm Drug, Inc
Drug class
HIV medicine
NDC
67296-1237, 61958-0701, 67296-1237-4, 67296-1237-3

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Truvada pills and guides

What is Truvada used for?

Truvada is used for HIV and hepatitis B.

Medicine type
HIV medicine
Official uses from the US prescribing label

1.1 Treatment of HIV-1 Infection

TRUVADA®, a combination of EMTRIVA® and VIREAD®, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 17 kg.

The following points should be considered when initiating therapy with TRUVADA for the treatment of HIV-1 infection:

It is not recommended that TRUVADA be used as a component of a triple nucleoside regimen. TRUVADA should not be coadministered with ATRIPLA®, COMPLERA®, DESCOVY®, EMTRIVA, GENVOYA®, ODEFSEY®, STRIBILD®, VEMLIDY®, VIREAD, or lamivudine-containing products. In treatment experienced patients, the use of TRUVADA should be guided by laboratory testing and treatment history.

1.2 Pre-Exposure Prophylaxis

TRUVADA is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk. This indication is based on clinical trials in men who have sex with men (MSM) at high risk for HIV-1 infection and in heterosexual serodiscordant couples.

When considering TRUVADA for pre-exposure prophylaxis the following factors may help to identify individuals at high risk:

has partner(s) known to be HIV-1 infected, or engages in sexual activity within a high prevalence area or social network and one or more of the following:

inconsistent or no condom use diagnosis of sexually transmitted infections exchange of sex for commodities (such as money, food, shelter, or drugs) use of illicit drugs or alcohol dependence incarceration partner(s) of unknown HIV-1 status with any of the factors listed above

When prescribing TRUVADA for pre-exposure prophylaxis, healthcare providers must:

prescribe TRUVADA as part of a comprehensive prevention strategy because TRUVADA is not always effective in preventing the acquisition of HIV-1 infection; counsel all uninfected individuals to strictly adhere to the recommended TRUVADA dosing schedule because the effectiveness of TRUVADA in reducing the risk of acquiring HIV-1 was strongly correlated with adherence as demonstrated by measurable drug levels in clinical trials; confirm a negative HIV-1 test immediately prior to initiating TRUVADA for a PrEP indication. If clinical symptoms consistent with acute viral infection are present and recent (<1 month) exposures are suspected, delay starting PrEP for at least one month and reconfirm HIV-1 status or use a test approved by the FDA as an aid in the diagnosis of HIV-1 infection, including acute or primary HIV-1 infection; and screen for HIV-1 infection at least once every 3 months while taking TRUVADA for PrEP.

From the FDA-approved label on DailyMed (published Jul 16, 2024).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • One side shows GILEAD and the other side shows 701.
  • It is blue, capsule, 19 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Ingredients

Active: Emtricitabine, Tenofovir Disoproxil Fumarate

Inactive: Hypromellose, Unspecified, Titanium Dioxide, Magnesium Stearate, Starch, Corn, Fd&c Blue No. 2, Aluminum Oxide, Croscarmellose Sodium, Lactose Monohydrate, Microcrystalline Cellulose, Water, Triacetin

Other pills with imprint GILEAD 701

Same imprint, different listing. Check the color, size and maker against your pill.

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.